LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals
Strategic acquisition to expand pipeline, accelerate growth, and meet unmet needs in medical dermatology.
Ballerup January 23, 2024 - LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing.
The TMB-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. The TMB-001 project continues as planned and without changes within LEO Pharma. All employees of Timber Pharmaceuticals will transition to LEO Pharma’s offices in New Jersey, US.
TMB-001 is an investigational topical reformulation of the active pharmaceutical ingredient (API), isotretinoin that today only exists in an oral formulation in the U.S. The reformulation has received orphan, fast track, and breakthrough designation by the FDA. TMB-001 has shown positive results in Phase 2, with Phase 3 recruitment currently on-going in the US and in Europe.
Christophe Bourdon, CEO of LEO Pharma, commented:
- We are excited to kick-off 2024 by adding TMB-001 to our pipeline and to welcome the employees of Timber Pharmaceuticals to LEO Pharma. The transaction will further strengthen our pipeline with a strategic Phase 3 asset that has the potential to be able to help people living with a debilitating disease for which there are currently no proper treatment options.
LEO Pharma expects the acquisition to strengthen its US business. The transaction will not have a material financial impact on LEO Pharma’s financial results for 2024.
--ENDS--
Kontakter
Henrik Heskjær
Tlf:+45 3140 6180hdtdk@leo-pharma.comAbout LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
For further information, visit:
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma Presents Late-breaking Tralokinumab Data at EADV 2024 for Moderate-to-Severe Atopic Dermatitis (AD) in the Difficult-to-Treat Head and Neck Region27.9.2024 15:00:00 CEST | Pressemeddelelse
Real-world findings showed that subgroup of patients treated with Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) and with head and neck (H&N) atopic dermatitis (AD) at baseline reported presence of AD in that area in 52.1% of patients after nine months of treatment.(1) As part of one of LEO Pharma’s most extensive scientific programs at EADV to date, the late-breaking presentation examined interim data from the real-world TRACE study of adult AD patients who have been prescribed Adtralza/Adbry for up to nine months.(1) Additional posters presented interim results of the TRACE study on effectiveness of Adtralza/Adbry treatment through various physician and patient reported outcomes such as improvements in Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), itch, sleep disturbance and quality of life.(2,3)
LEO Pharma submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China27.9.2024 12:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Enstilar® (LEO 90100) to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA). The NDA is supported by results from a phase 3 trial comparing the efficacy and safety of Enstilar with Daivobet® ointment in adult Chinese patients.(1,2) The Enstilar submission demonstrates LEO Pharma's commitment to providing additional treatment options for the estimated seven million adult patients living with plaque psoriasis in China.(3)
LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting26.9.2024 14:30:00 CEST | Pressemeddelelse
Results presented at the Late Breaker Session on September 26th at the European Dermatology Congress, European Academy of Dermatology & Venereology (EADV) 2024, showed that the investigational interleukin 22 receptor, alpha 1 (IL-22RA1) inhibitor temtokibart induced fast (Week 1) molecular responses(1) Markers of skin hydration (natural moisturizing factors) 2-pyrrolidone-5-carboxylic acid (PCA) and urocanic acid (UCA) were significantly improved from baseline at Week 1 in the temtokibart group (p<0.0001)(1) Both temtokibart and dupilumab led to comparable changes in eczema area and severity index (EASI) and itch numerical rating scale (NRS) at Week 16(1)
LEO Pharma Presents Late-Breaking Anzupgo® (delgocitinib) Cream Presentation at EADV 2024 Highlighting Results of Head-to-Head DELTA FORCE Trial in Chronic Hand Eczema (CHE)25.9.2024 15:45:00 CEST | Pressemeddelelse
The full DELTA FORCE results, the first of three Anzupgo® (delgocitinib) cream late-breaking presentations at the congress, demonstrated that topical treatment with delgocitinib cream had a significantly higher efficacy compared to oral alitretinoin capsules among adult patients with severe CHE.(1) Six other pieces of investigational delgocitinib cream research form part of LEO Pharma’s extensive scientific program at EADV 2024.(2-7) Remaining abstracts include post hoc analysis of the DELTA 1, 2, and 3 trials showing efficacy data for delgocitinib cream across five different CHE subtypes, clinician-reported real-world findings, large-scale patient prevalence data, and detailed analysis of patient biopsy samples.(2-7)
LEO Pharma Unveils Most Extensive EADV Program To Date with 5 Late Breaking Abstracts and 23 Posters Sharing Clinical and Real-World Data25.9.2024 10:00:00 CEST | Pressemeddelelse
LEO Pharma will demonstrate true leadership in medical dermatology by presenting one of its largest ever scientific programs to date at this year’s EADV congress, with 5 late-breaking presentations and 23 scientific posters in total.(1-28) New late-breaking Anzupgo® (delgocitinib) cream data will include the full results of the Phase 3 head-to-head DELTA FORCE trial, as well as a wide range of associated clinical and real-world findings on delgocitinib cream and moderate to severe chronic hand eczema (CHE).(1-6) Additional late-breaking data includes a presentation of Adtralza® (tralokinumab)/Adbry ® (tralokinumab-ldrm) interim data from the real-world TRACE study on the effectiveness of Adtralza/Adbry in adults with moderate to severe head and neck atopic dermatitis (AD).(27) Finally, a late-breaking presentation will discuss the first randomized trial comparing clinical and molecular effects of temtokibart and dupilumab in moderate to severe AD.(28)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum